Effective date
Medicare changes effective January 22, 2026
28 CMS and MAC policy updates take effect on this date across 2 MAC jurisdictions. Every entry links to the government document it came from.
CMS Coverage API · 28
- LCD L38288: MolDX: Repeat Germline Testing — CGS
LCD-L38288CGS AdministratorsOncologysource ↗
- LCD L37897: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer — Noridian
LCD-L37897NoridianOncologysource ↗
- LCD L39944: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease — Noridian
LCD-L39944NoridianCardiologysource ↗
- LCD L39686: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers — Noridian
LCD-L39686NoridianOncologysource ↗
- LCD L38331: MolDX: Blood Product Molecular Antigen Typing — Noridian
LCD-L38331NoridianInfectious Disease / Microbiologysource ↗
- LCD L37887: MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test — Noridian
LCD-L37887NoridianPulmonologysource ↗
- LCD L37822: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — Noridian
LCD-L37822NoridianOncologysource ↗
- LCD L37295: MolDX: EndoPredict® Breast Cancer Gene Expression Test — Noridian
LCD-L37295NoridianOncologysource ↗
- LCD L36380: MolDX: Breast Cancer Assay: Prosigna® — Noridian
LCD-L36380NoridianOncologysource ↗
- LCD L36155: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) — Noridian
LCD-L36155NoridianHematologysource ↗
- LCD L39589: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — Noridian
LCD-L39589NoridianDermatologysource ↗
- LCD L39467: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — Noridian
LCD-L39467NoridianRheumatologysource ↗
- LCD L39373: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma — Noridian
LCD-L39373NoridianDermatologysource ↗
- LCD L39262: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia — Noridian
LCD-L39262NoridianGastroenterologysource ↗
- LCD L39005: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
LCD-L39005NoridianOncologysource ↗
- LCD L37750: MolDX: Melanoma Risk Stratification Molecular Testing — Noridian
LCD-L37750NoridianOncologysource ↗
- LCD L37126: Coenzyme Q10 (CoQ10) — CGS
LCD-L37126CGS AdministratorsCardiologysource ↗
- LCD L39616: Urinary Biomarkers for Chronic Pain Management — CGS
LCD-L39616CGS AdministratorsPain Managementsource ↗
- LCD L34008: Computerized Corneal Topography — CGS
LCD-L34008CGS AdministratorsOphthalmologysource ↗
- LCD L33999: Corneal Pachymetry — CGS
LCD-L33999CGS AdministratorsOphthalmologysource ↗
- LCD L34062: Dialysis Access Maintenance — CGS
LCD-L34062CGS AdministratorsESRDsource ↗
- LCD L34005: Colonoscopy/Sigmoidoscopy/Proctosigmoidoscopy — CGS
LCD-L34005CGS AdministratorsGastroenterologysource ↗
- LCD L39678: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy — Noridian
LCD-L39678NoridianPulmonologysource ↗
- LCD L37070: MolDX: DecisionDx-UM (Uveal Melanoma) — Noridian
LCD-L37070NoridianOncologysource ↗
- LCD L36551: MolDX: HLA-DQB1*06:02 Testing for Narcolepsy — Noridian
LCD-L36551NoridianNeurologysource ↗
- LCD L39521: Positron Emission Tomography (PET) Scan for Inflammation and Infection — CGS
LCD-L39521CGS AdministratorsRadiologysource ↗
- LCD L36358: MolDX: Biomarkers in Cardiovascular Risk Assessment — Noridian
LCD-L36358NoridianCardiologysource ↗
- LCD L36188: MolDX: MGMT Promoter Methylation Analysis — Noridian
LCD-L36188NoridianOncologysource ↗